European HTA agencies launch the Heads of Agencies Group (HAG)
FDA-EMA Parallel Scientific Advice Pilot program for complex generic/hybrid products
Value-based pricing of prescription drugs benefits patients and promotes innovation
We provide an overview of the product life cycle
We examine the effects on patient access, specifically regarding pathways, high value steps, multi-i...
Our analysts explore NICE's integration of tech appraisals into treatment guidelines for to enable o...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.